STUDY DESIGN: Report of 2 cases of sarcoidosis involving vertebrae successfully treated with tumor necrosis factor-α inhibitor (TNF-α antagonist). OBJECTIVE: To disseminate knowledge concerning successful treatment of sarcoidosis involving the axial skeleton with the use of TNF-α blockers. SUMMARY OF BACKGROUND DATA: Osseous sarcoidosis most commonly involves small bones of hands and feet; vertebral involvement is rare, and currently there is no consensus on optimal treatment. METHODS: Two cases are described detailing patients with extrapulmonary sarcoidosis involving vertebral bodies, retractable to conventional treatment, who were treated with TNF-α antagonists. RESULTS: We observed a remarkable response following the administration of TNF-α blockers in vertebral sarcoidosis with marked resolution of lytic lesions. The patients remained asymptomatic with no recurrence of their disease. CONCLUSION: Vertebral sarcoidosis is a rare manifestation of osseous sarcoidosis. Symptomatic patients are treated with various immunosuppressive therapies. We propose utilizing TNF-α blocking agents in patients who fail to respond to first-line therapy.
STUDY DESIGN: Report of 2 cases of sarcoidosis involving vertebrae successfully treated with tumor necrosis factor-α inhibitor (TNF-α antagonist). OBJECTIVE: To disseminate knowledge concerning successful treatment of sarcoidosis involving the axial skeleton with the use of TNF-α blockers. SUMMARY OF BACKGROUND DATA: Osseous sarcoidosis most commonly involves small bones of hands and feet; vertebral involvement is rare, and currently there is no consensus on optimal treatment. METHODS: Two cases are described detailing patients with extrapulmonary sarcoidosis involving vertebral bodies, retractable to conventional treatment, who were treated with TNF-α antagonists. RESULTS: We observed a remarkable response following the administration of TNF-α blockers in vertebral sarcoidosis with marked resolution of lytic lesions. The patients remained asymptomatic with no recurrence of their disease. CONCLUSION:Vertebral sarcoidosis is a rare manifestation of osseous sarcoidosis. Symptomatic patients are treated with various immunosuppressive therapies. We propose utilizing TNF-α blocking agents in patients who fail to respond to first-line therapy.
Authors: Nadera J Sweiss; Imre Noth; Mehdi Mirsaeidi; Wei Zhang; Edward T Naureckas; D Kyle Hogarth; Mary Strek; Philip Caligiuri; Roberto F Machado; Timothy B Niewold; Joe G N Garcia; Aileen L Pangan; Robert P Baughman Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2014-04-18 Impact factor: 0.670
Authors: Ezra Ross Miller; Christopher H Fanta; Jakob I McSparron; Beatrice Pan; Jonathan S Coblyn; Jeffrey A Sparks Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2019-03-11 Impact factor: 0.670
Authors: Julien Stievenart; Guillaume Le Guenno; Marc Ruivard; Virginie Rieu; Marc André; Vincent Grobost Journal: Front Cardiovasc Med Date: 2021-06-11